March 18, 2021 12:53 PM EDT

Recall report: Sagent Pharma pulls low blood pressure med for loose sealing on sterile vials

Kyle Blankenship

Sagent Pharmaceuticals has recalled three lots of its phenylephrine hydrochloride injection after a customer complaint noted “potentially loose crimped vial seals” …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Recall report: Sagent Pharma pulls low blood pressure med for loose sealing on sterile vials

Kyle Blankenship

Sign up to read this article for free.

The brain is Eli Lilly's next target for its obesity meds

Lilly’s oral SERD makes strides in breast cancer with Phase 3 data

The Endpoints 100: The biotech industry braces for Trump 2.0

Gene editing companies seek safer, less grueling conditioning methods for blood stem cell therapies

Acelyrin says goodbye to the drug that got it a $540M IPO in 2023

The key to faster, more impactful research? Put patients in the driver’s seat

Re­call re­port: Sagent Phar­ma pulls low blood pres­sure med for loose seal­ing on ster­ile vials

Kyle Blankenship

Sign up to read this article for free.

The brain is Eli Lil­ly's next tar­get for its obe­si­ty meds

Lil­ly’s oral SERD makes strides in breast can­cer with Phase 3 da­ta

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Gene edit­ing com­pa­nies seek safer, less gru­el­ing con­di­tion­ing meth­ods for blood stem cell ther­a­pies

Ace­lyrin says good­bye to the drug that got it a $540M IPO in 2023

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

Recall report: Sagent Pharma pulls low blood pressure med for loose sealing on sterile vials

The brain is Eli Lilly's next target for its obesity meds

Lilly’s oral SERD makes strides in breast cancer with Phase 3 data

The Endpoints 100: The biotech industry braces for Trump 2.0

Gene editing companies seek safer, less grueling conditioning methods for blood stem cell therapies

Acelyrin says goodbye to the drug that got it a $540M IPO in 2023

The key to faster, more impactful research? Put patients in the driver’s seat